Enovis Corporation

Ladies and gentlemen, thank you for standing by and welcome to the Enovus third quarter 2022 earnings call. I would now like to turn the call over to Derek Lecco, Vice President of Investor Relations. Please go ahead.

Thank you. Good morning, everyone. Thank you for joining us today for our third quarter results conference call. I'm Derek Leko, Vice President of Investor Relations. And joining me on the call today are Matt Triartola, CEO, and Chris Hicks, Executive Vice President and CFO, and Ben Barry, who we previously announced will serve as Inovus' CFO when Chris retires at the end of the year. Our earnings release was issued earlier this morning and is available in the investor relations section of our website, inovus.com. We'll be using a slide presentation of today's call which can also be found on our website. Both the audio and the slide presentation of this call will be archived on the website later today. During this call, we'll make some forward-looking statements about our beliefs and estimates regarding future events and results. These forward-looking statements are subject to risks and uncertainties, including those set forth in the Safe Harbor language in today's earnings release and in our with the SEC. Actual results may differ materially from any statements that we make today. Forward-looking statements speak only as of today, and we do not assume any obligation or intend to update them except as required by law. With respect to any non-GAAP financial measures referenced during the call today, the accompanying reconciliation information relating to those measures can be found in our earnings press release and in the appendix of today's slide presentation. With that, let me turn the call over to Matt on slide three.

Thanks, Derek. I'm pleased to discuss our great operating and strategic progress this quarter. We had strong growth and are demonstrating clear strides toward our strategic goal of sustainable, high single-digit organic growth. Our growth is supported by an innovation engine that continues to produce exciting new technologies and solutions to improve patient outcomes and healthcare workflows. In a moment, I'll discuss the latest P&R product offering that highlights our innovation vitality and momentum. Despite a high load of inflation on our results, we continue to improve our core margins this quarter, aided in part by price versus cost progress and operating leverage from our strong sales growth.